Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449280 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00449280 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 34 participants.
The verdict
NCT00449280, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
Interventions
- DRUG Sorafenib
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449280
The ClinicalTrials.gov registry entry for NCT00449280 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00449280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449280 about?
NCT00449280 is a clinical study titled "Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies". The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
What is the current status of trial NCT00449280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00449280?
The interventions under investigation include: Sorafenib (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00449280?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.